About 100 guests from 36 countries met on the XVIII. MetaSystems Distributor Meeting (DM) in November to exchange experiences and to get to know new trends and developments at MetaSystems.

Our internet site may contain information that is not approved in all countries or regions. To ensure accuracy of content, please select your country/region of residence. Choose International if your country is not listed.
This information will be saved using cookies. To find out more about cookies, read our Privacy Policy.
Please select your country of residence. Choose International if your country is not listed.
Our internet site may contain information that is not approved in all countries or regions. To ensure accuracy of content, it is required that you select the site which is appropriate for your country of residence.
XL ALK BA consists of an orange-labeled probe hybridizing to a region within the ALK gene at 2p23 and a green-labeled probe hybridizing distal to the ALK gene region at 2p23.
Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.
The EML4/ALK fusion gene is responsible for approximately 3-5% of non-small-cell lung cancer (NSCLC). The vast majority of cases are adenocarcinomas. Two other fusion partners of ALK have been reported in lung cancer - TFG and KIF5B. Up to 12 other translocation partners have been described in anaplastic large-cell lymphomas (ALCL), renal cancer, esophageal squamous cell, colon, and breast carcinoma. Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase which was discovered in anaplastic large-cell lymphoma (ALCL).
The formation of a fusion protein with a partner through chromosomal translocations is the most common mechanism of ALK overexpression and ALK kinase domain activation. The ALK inhibitor crizotinib has increased the significance of detecting ALK rearrangements in lung cancer and ALCL.
Normal Cell:
Two green-orange colocalization/fusion signals (2GO).
Aberrant Cell (typical results):
One green-orange colocalization/fusion signal (1GO), one separate green (1G) and orange (1O) signal each resulting from a chromosome break in the relevant locus.
Aberrant Cell (typical results):
Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.
Certificate of Analysis (CoA)
or go to CoA Database